Science
The company’s scientific platform is built on the novel discovery of a unique mast cell receptor that controls the entire mast cell activity unlocking the potential for transformative treatments with superior efficacy and a strong safety profile.
Dr. Mikael Dolsten, board chairman of MC Sciences, “Based on human pharmacology, the MC Sciences team has identified novel mast cell biology that represents the most promising opportunity in decades to effectively treat mast cell-related diseases with a high likelihood of translational success in humans. I’m excited to support MC Sciences in bringing these groundbreaking therapeutics to patients.”
Superior Therapeutic Profile
Superior Therapeutic Efficacy with complete silencing of selectively dysfunctional and activated mast cells with therapeutic efficacy on all
disease-driving pathways (independent of the activation trigger).
Excellent Safety as only activated mast cells that are disease-driving are selectively targeted resulting in no immune-suppressive side effects.
Broad Therapeutic and Multi-Symptom Treatment of multiple diseases and related symptoms (e.g. skin, gastrointestinal, lung) with ability to target mast cells in all organs with similar dosing.
Potentially Disease-Modifying reversing disease progress over time (“turning back the disease clock”) by reduction of accumulated mast cells.
In-human validated pharmacology and corresponding human ex-vivo and
in-vivo model validation with expected high probability for clinical success.
Wolfgang Taumann, co-founder and CEO of MC Sciences, “Finding the key to control dysfunctional and chronically activated mast cells, the underlying cause of so many major diseases with high need, is an unique opportunity to develop transformative highly effective and safe treatments and finally bring these to so many patients with high need”
